Company Announcements

Additional Listing

Source: RNS
RNS Number : 6075M
BBGI SICAV S.A.
12 May 2020
 

12 May 2020

 

BBGI SICAV S.A.

(the "Company")

 

Additional Listing

 

BBGI SICAV S.A. (LSE ticker: BBGI), the international PPP infrastructure investment company, announces that application has been made for 690,274 ordinary shares of no par value in the Company ("Shares") to be admitted to the Official List of the FCA and to trading on the London Stock Exchange. It is expected that Admission will become effective and dealings in the new shares will commence at 8.00 a.m. on 14 May 2020. Following Admission, the number of ordinary shares the Company has in issue will be 631,169,721.

 

The application is being made pursuant to the LTIP awards for 2016-2019, originally granted on 21 December 2016. When issued, these Shares will rank pari passu with the existing ordinary shares.

 

 

For further information, please contact:

 

BBGI Management Team          +352 263 479-1

Duncan Ball

Frank Schramm

 

 

BBGI is a FTSE 250 company and owns a global portfolio of 49 infrastructure assets. These are PPP assets and are supported by contracted, public sector-backed revenue streams, with inflation-protection characteristics.

 

Further information about BBGI is available on its website at www.bb-gi.com *.

 

The Company's LEI is: 529900CV0RWCOP5YHK95

 

Any reference to the Company or BBGI refers also to its subsidiaries (where applicable).

 

* Neither the Company's website nor the content of any website accessible from hyperlinks on its website (or any other website) is (or is deemed to be) incorporated into, or forms (or is deemed to form) part of this announcement.

 

 

 

 

 

 

                                                                    

 

 

 

 

                                                                        


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSKKBBQBBKKKPD